Analysts Set Vaxcyte, Inc. (NASDAQ:PCVX) Target Price at $97.83

Vaxcyte, Inc. (NASDAQ:PCVX) has earned an average recommendation of “Moderate Buy” from the ten brokerages that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $97.8333.

Several equities analysts have issued reports on the stock. BTIG Research restated a “buy” rating and issued a $85.00 price target on shares of Vaxcyte in a research report on Monday, November 10th. Leerink Partners set a $77.00 target price on Vaxcyte and gave the company an “outperform” rating in a report on Wednesday, November 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a report on Tuesday, October 14th. Finally, The Goldman Sachs Group initiated coverage on shares of Vaxcyte in a research report on Friday, September 12th. They issued a “neutral” rating and a $38.00 price target on the stock.

Hedge Funds Weigh In On Vaxcyte

Several hedge funds and other institutional investors have recently bought and sold shares of PCVX. AlphaQuest LLC acquired a new stake in Vaxcyte during the 1st quarter worth about $33,000. BI Asset Management Fondsmaeglerselskab A S acquired a new position in shares of Vaxcyte during the 1st quarter valued at $35,000. Allworth Financial LP boosted its stake in Vaxcyte by 148.9% during the third quarter. Allworth Financial LP now owns 1,222 shares of the company’s stock worth $44,000 after acquiring an additional 731 shares in the last quarter. Aster Capital Management DIFC Ltd acquired a new stake in Vaxcyte in the third quarter worth $45,000. Finally, CIBC Private Wealth Group LLC increased its stake in Vaxcyte by 22,500.0% in the third quarter. CIBC Private Wealth Group LLC now owns 1,356 shares of the company’s stock valued at $49,000 after purchasing an additional 1,350 shares in the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.

Vaxcyte Trading Down 0.4%

Vaxcyte stock opened at $47.64 on Monday. The stock has a 50-day moving average price of $45.32 and a two-hundred day moving average price of $38.16. Vaxcyte has a 12 month low of $27.66 and a 12 month high of $93.77. The company has a market capitalization of $6.24 billion, a PE ratio of -9.84 and a beta of 1.28.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($1.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by ($0.29). During the same quarter in the prior year, the business earned ($0.83) earnings per share. As a group, analysts predict that Vaxcyte will post -4.21 earnings per share for the current fiscal year.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.